Low molecular weight heparins as antineoplastic agents.

Risultato della ricerca: Article

Abstract

There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.
Lingua originaleEnglish
pagine (da-a)159-161
Numero di pagine3
RivistaRecent Patents on Anti-Cancer Drug Discovery
Volume3
Stato di pubblicazionePublished - 2008

Fingerprint

Low Molecular Weight Heparin
Antineoplastic Agents
Fibrinolytic Agents
Patents
Venous Thromboembolism
Neoplasms
Survival
Therapeutics

Cita questo

@article{bdc204168c1044dbb5830cd7c36511ee,
title = "Low molecular weight heparins as antineoplastic agents.",
abstract = "There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.",
keywords = "Low molecular weight heparin, cancer, therapy",
author = "Sergio Siragusa",
year = "2008",
language = "English",
volume = "3",
pages = "159--161",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Low molecular weight heparins as antineoplastic agents.

AU - Siragusa, Sergio

PY - 2008

Y1 - 2008

N2 - There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.

AB - There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.

KW - Low molecular weight heparin

KW - cancer

KW - therapy

UR - http://hdl.handle.net/10447/47399

M3 - Article

VL - 3

SP - 159

EP - 161

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

ER -